Loading…
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-112M | $-106M | $-85M | -77.6% | - | - |
| 2024 | $0M | $-95M | $-87M | $-81M | -57.2% | - | - |
| 2023 | $0M | $-84M | $-76M | $-65M | -33.8% | - | - |
| 2022 | $0M | $-59M | $-59M | $-56M | -30.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 60.30 | 84.99 | 96.12 | 112.79 |
| Operating Income | -60.30 | -84.99 | -96.12 | -112.79 |
| EBITDA | -59.12 | -83.70 | -94.89 | -111.66 |
| EBIT | -60.30 | -84.99 | -96.12 | -112.79 |
| Pretax Income | -58.76 | -76.27 | -86.81 | -106.08 |
| Tax Provision | 0 | 0.14 | 0.11 | 0.11 |
| Net Income | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income Common Stockholders | -58.76 | -76.41 | -86.92 | -106.19 |
| Total Expenses | 60.30 | 84.99 | 96.12 | 112.79 |
| Interest Income | 1.86 | 8.59 | 9.43 | 6.63 |
| Research And Development | 42.24 | 65.23 | 73.30 | 90.30 |
| Selling General And Administration | 18.06 | 19.76 | 22.81 | 22.49 |
| Normalized EBITDA | -58.80 | -83.90 | -94.89 | -111.66 |
| Normalized Income | -58.45 | -76.62 | -86.92 | -106.19 |
| Basic EPS | -1.96 | -1.93 | -1.75 | -1.76 |
| Diluted EPS | -1.96 | -1.93 | -1.75 | -1.76 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -0.32 | 0.21 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | -0.32 | 0.21 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -58.76 | -76.41 | -86.92 | -106.19 |
| Reconciled Depreciation | 1.18 | 1.29 | 1.22 | 1.13 |
| Net Interest Income | 1.86 | 8.59 | 9.43 | 6.63 |
| Net Income From Continuing And Discontinued Operation | -58.76 | -76.41 | -86.92 | -106.19 |
| Total Operating Income As Reported | -60.30 | -84.99 | -96.12 | -112.79 |
| Diluted Average Shares | 29.94 | 39.62 | 49.65 | 60.34 |
| Basic Average Shares | 29.94 | 39.62 | 49.65 | 60.34 |
| Diluted NI Availto Com Stockholders | -58.76 | -76.41 | -86.92 | -106.19 |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -58.76 | -76.41 | -86.92 | -106.19 |
| Net Income Continuous Operations | -58.76 | -76.41 | -86.92 | -106.19 |
| Other Income Expense | -0.33 | 0.13 | -0.12 | 0.08 |
| Other Non Operating Income Expenses | -0.01 | -0.08 | -0.12 | 0.08 |
| Special Income Charges | -0.32 | 0.21 | 0 | 0 |
| Gain On Sale Of Ppe | -0.32 | 0.21 | 0 | 0 |
| Gain On Sale Of Security | -0.01 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 1.86 | 8.59 | 9.43 | 6.63 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 1.86 | 8.59 | 9.43 | 6.63 |
| General And Administrative Expense | 18.06 | 19.76 | 22.81 | 22.49 |
| Other Gand A | 18.06 | 19.76 | 22.81 | 22.49 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aura Biosciences, Inc.this co. | AURA | $432M | - | 3.13 | -77.6% | -2.73 |
| Beta Bionics, Inc. | BBNX | $441M | - | 1.63 | -25.5% | -3.29 |
| AngioDynamics, Inc. | ANGO | $440M | - | 2.56 | -18.6% | -634.17 |
| Atea Pharmaceuticals, Inc. | AVIR | $435M | - | 1.54 | -57.5% | -0.73 |
| REGENXBIO Inc. | RGNX | $434M | - |
| 4.16 |
| -188.7% |
| -3.19 |
| Evolent Health, Inc. | EVH | $432M | - | 1.02 | -128.7% | 14.29 |
| Fulgent Genetics, Inc. | FLGT | $427M | - | 0.41 | -5.5% | -1.98 |
| Vanda Pharmaceuticals Inc. | VNDA | $424M | - | 1.27 | -67.4% | -1.16 |
| Strata Critical Medical, Inc. | SRTA | $424M | - | 1.52 | 14.8% | -64.52 |
| Peer Median | - | - | 1.53 | -41.5% | -2.58 | |